Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Hoffmann-La Roche
National Cancer Institute (NCI)
University of Michigan Rogel Cancer Center
Wake Forest University Health Sciences
Jazz Pharmaceuticals
Dana-Farber Cancer Institute
Janssen Pharmaceutical K.K.
Mayo Clinic
Baylor College of Medicine
Avacta Life Sciences Ltd
Mayo Clinic
Brigham and Women's Hospital
NRG Oncology
University Health Network, Toronto
Big Ten Cancer Research Consortium
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
VM Oncology, LLC
Bayer
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
LigaChem Biosciences, Inc.
Merck Sharp & Dohme LLC
Peking Union Medical College
Abramson Cancer Center at Penn Medicine
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
QBiotics Group Limited
Dana-Farber Cancer Institute
National University Hospital, Singapore
Dana-Farber Cancer Institute
National Cancer Center Hospital East
University of Cincinnati
Poseida Therapeutics, Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
University of Washington
European Organisation for Research and Treatment of Cancer - EORTC
University of Chicago
Convalife (Shanghai) Co., Ltd.
Universitair Ziekenhuis Brussel
Northwestern University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Canadian Cancer Trials Group